Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.

New insights into the molecular biology of childhood leukemias have stimulated numerous advances in diagnostic methods, strategies for risk assessment and the development of novel therapy for genetic subtypes of the diseases. Fully revised and updated, this new edition of Childhood Leukemias provides the most comprehensive, clinically-oriented and authoritative reference dedicated to these diseases. Beginning with an overview of history, cell biology, and pathology, subsequent chapters review approaches in the evaluation and management of specific leukemias, new therapeutic development and the unique pharmacodynamics and pharmacogenetics of individual patients. New chapters include epigenetics of leukemias, leukemias in patients with Down syndrome and leukemia in adolescents and young adults. The final section covers the complications associated with the disease or its treatment and supportive care during and after treatment. Authored by leading experts, this is a 'must-have' for any physician or investigator who deals with leukemias in childhood.

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials. Topics include: Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors) Ras inhibitors Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors) Lenalidomide analogs New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib) New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40) Thrombopoietic agents Leukemias: Principles and Practice of Therapy Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area

Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.

Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.

This book provides an overview of the key developments in both acute lymphocytic leukemia and acute myeloid leukemia with a comprehensive guide to the epidemiology, pathogenesis, etiology, clinical manifestations, classification, diagnosis, and staging as well as the most recent developments in the therapeutic landscape for acute leukemia. The Handbook of Acute Leukemia offers readers a key resource into the future outlook for patients with leukemia and is edited and authored by internationally renowned experts in the field. Leukemia is cancer of the white blood cells and acute leukemia means the condition progresses rapidly and aggressively, requiring immediate treatment. Acute leukemia is classified according to the type of white blood cells that are affected: either lymphocytes and myeloid cells.

Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment provides a comprehensive and concise visual reference on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) seen in children and adults. This book addresses all aspects of AML and ALL including their risk factors, cytogenetics and mutational characteristics, diagnoses, clinical management and prognoses which are imperative and challenging for medical students, residents, hematology and medical oncology fellows, and even community oncologists and hematologists. It presents complex information relying predominantly on pictorial depictions rather than traditional text in a visually instructive format. It replaces the wordiness of a traditional textbook with original and adapted illustrations, instructive schemata and diagrams, photomicrographs, tables, detailed figure legends, and practical, ‘bite-sized’ text. The result is a visually engaging book that is easy to read, review, and remember. Crafted by world experts in the field, this digestible volume provides you with the must-know information that you can utilize when encountering AML and ALL patients who require immediate attention. Whether you are an early-career practitioner looking for quick guidance to managing a deadly disease or you are a seasoned clinician looking for a quick review of treatment protocols, this engaging format provides a unique and ‘go-to’ resource. Key Features: Contains over 40 tables and over 220 illustrations, histologic photomicrographs, flow diagrams, graphs, and schemata with detailed figure legends Presents complex scientific aspects such as cytogenetics and molecular mutations in a visually digestible and easy-to-understand format Provides helpful and evidence-based treatment recommendations when providing induction therapy, consolidation therapy, and bone marrow transplantation Includes unique chapters on managing psychosexual issues accompanying AML and ALL treatment as well as on the FDA drug development and clinical trial design process Includes digital access to the e-book as well as an online Image Bank

A brand-new edition of the bestselling guide to hematologic malignancies. An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers. Following on the successful steps of the first edition, this Second Edition covers: various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantation side-effects of various treatments future prospects for leukemia, lymphoma, and myeloma targeted therapies and history of the cancers information and support sources for patients

Written by over 50 internationally distinguished experts, 30 more than the first edition, and contains nine new chapters! Continuing in the esteemed tradition and heralded success of the first edition, Chronic Lymphoid Leukemias, Second Edition offers a full overview of chronic lymphocytic leukemia (CLL) from multiple perspectives-covering all major developments since the previous edition was published eight years ago. Chronicling the complete history and variations of CLL-type leukemia, the Second Edition reviews the origin, nature, and molecular differences between B-CLL and T-CLL/PLL leukemias analyzes core constituents of apoptosis and causes for dysregulation of programmed cell death (PCD) in B-CLL examines recent research on the role cytokines and regulatory molecules may play in cross-cell communication profiles commonly used vectors for somatic gene therapy, as well as the latest advances in genetic engineering and vector design and production utilizes up-to-the-minute techniques such as fluorescence in-situ hybridization (FISH) and comparative genomic hybridization (CGH) to detect genetic abnormalities and aberrations explores current measures of supportive care with splenectomy, cytokine proteins, and intravenous immunoglobulin applications identifies how to manage infectious and psychiatric complications in patients with CLL and much more! Provides contemporary results on the efficacy of nucleoside analog combinations such as ara-C with fludarabine and cladribine and on the emerging nucleosides nelarabine and clofarabine! Copiously supplemented with over 2500 literature references-1000 more than the first edition-Chronic Lymphoid Leukemias, Second Edition fulfills the reference needs of oncologists, hematologists, immunologists, pathologists, infectious disease specialists, internists, molecular biologists, and medical school students in these disciplines.

This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students.